The Next Alzheimer’s Breakthrough Will Take More Than Just Science

John Hardy says new anti-amyloid drugs like Lecanemab and Donanemab are a major breakthrough because they can remove existing amyloid and slow Alzheimer’s decline.

But these drugs do not stop the disease, and he says stronger biomarkers and earlier diagnosis are still needed to help patients sooner.

He also warns that scientific progress will have limited impact without political funding for dementia services and broader health-system support.

The article’s core point: Alzheimer’s treatment is advancing, but real-world benefit depends on access, diagnosis, and investment.